Advanced NSCLC Clinical Trial
Official title:
A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar(rh Recombined Endostatin)With Single Docetaxel In NSCLC Patients
The purpose of this study is to compare the efficacy and safety of Endostar (Recombinant Human Endostatin) combined with Docetaxel and single Docetaxel through multi-center, double-blinding, randomized controlled, phase Ⅳ clinical trial for NSCLC cases who have obvious progressive disease or intolerant adverse effects in first-line chemotherapy.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | October 2010 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age 18-75 years old, males or females; 2. Patients with NSCLC confirmed by histopathology or cytology who need second-line chemotherapy, including progressive disease cases during or in 3 months posterior to end of first-line chemotherapy( at least 4 cycles done) and cases with intolerant adverse effects in first-line chemotherapy( at least 4 cycles done); neo-adjuvant chemotherapy and targeted therapy(EFGR-TKIs) not to be served as first-line chemotherapy; 3 months of clearance needed for neo-adjuvant chemotherapy and 1 month for targeted and first-line chemotherapy; 3. Local advanced and metastatic cases with tumor foci that can be evaluated by CT, MRI or PET-CT; at least one diameter = 1 cm (including metastatic lymph nodes) confirmed by CT scan or = 1 cm by spin CT or PET-CT ); 4. No contraindication for chemotherapy, with normal peripheral hemogram, renal and hepatic function: Peripheral hemogram: WBC=4.0×109/L,PLT=80×109/L,Hgb=90g/L; Renal function: serum BUN and creatinine =1.0×UNL; Hepatic function: transaminase=1.5×UNL, BIL=×UNL; 5. Karnofsky performance scale=60 or ECOG performance scale= 2; expected survival time=3 months; 6. No allergic history to biological agents and taxane agents; 7. Patients are voluntary to participate and sign the informed contents. Exclusion Criteria: 1. Pregnant or breast-feeding females; or females who have reproductive ability but do not take contraception method; 2. With severe acute infection uncontrolled; purulent or chronic infection with wounds difficult to recover; 3. With history of severe heart diseases, including congestive heart failure, uncontrolled arrhythmia with high risk, unstable angina pectoris, myocardial infarction, severe cardiac valvular diseases and refractory hypertension; 4. Patients with uncontrolled neurological, mental disease or psychosis, patients with poor compliance that cannot coordinate the therapy or describe the treatment response; 5. Uncontrolled brain metastasis patients with obvious manifestations of intracranial hypertension or neurological and mental disorders; 6. Uncontrolled diabetes and contraindication to corticoid agents; 7. Obvious hemorrhage tendency; 8. Allergic to any drug in the trial; 9. Patients with a second tumor; 10. Patients participating in other clinical trials; 11. Patients treated by Endostar or Docetaxel (excluding neo-chemotherapy) included combination chemotherapy previously; 12. Foci to be evaluated for response in trial treated by radiation in 6 months. 13. Other conditions that are regarded for exclusion by the trialists. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Cancer Hospital of Tianjin Medical University | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Simcere Pharmaceutical Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival time,survival rate for 1 year | two years (2010.10) | No | |
Secondary | Tumor response rate, disease controlled rate and adverse effects. | 1 year (2009.10) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04982224 -
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05609578 -
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
|
Phase 2 | |
Not yet recruiting |
NCT04992858 -
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
|
Phase 2 | |
Active, not recruiting |
NCT03127449 -
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
|
N/A | |
Not yet recruiting |
NCT06356675 -
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
|
Phase 4 | |
Completed |
NCT03074175 -
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer:Multicenter Controlled Study.(RadmiR-01)
|
N/A | |
Terminated |
NCT05106335 -
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT04229121 -
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
|
||
Completed |
NCT05219162 -
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
|
Phase 4 | |
Not yet recruiting |
NCT05859217 -
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
|
Phase 2 | |
Recruiting |
NCT03062800 -
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
|
Phase 2 | |
Completed |
NCT02055508 -
POSITIVE - Study (Part III) Heidelberg
|
N/A | |
Active, not recruiting |
NCT04043195 -
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
|
Phase 1/Phase 2 |